For prostate cancer screening, guidelines have little effect on clinical practice
the ONA take:
According to a new study published online in The Journal of the American Medical Association Internal Medicine, guidelines recommending that clinicians should not routinely screen elderly men for prostate cancer have had a minimal effect on practice. Researchers from Henry Ford Hospital in Detroit, Michigan, sought to find out whether a change in prostate screening guidelines by the U.S. Preventive Services Task Force (USPSTF) had altered practice in the last 3 years since the USPSTF recommended against routine prostate specific antigen (PSA) testing in any age group.
By using the 2012 Behavioral Risk Factor Surveillance System, the researchers examined which factors influence whether a patient is screened for prostate cancer, including access to health care, age, education, ethnicity/race, geographic location, income, insurance status, and marital status. They found that access to regular health care was strongly associated with increased rates of PSA screening.
In addition, they found an association between screening and an income greater than $75,000, higher education, health insurance, and an age between 70 and 74. Surprisingly, Hawaii has double the rate of PSA screening compared with New Hampshire.
The researchers suggest that the USPSTF guidelines have little effect on clinical practice.
Guidelines recommending not routinely screening have had a minimal effect on practice.
The effect of guidelines recommending that elderly men should not be routinely screened for prostate cancer "has been minimal at best," according to a new study led by researchers at Henry Ford Hospital.
The study, published as a research letter online in JAMA Internal Medicine, focused on the use of PSA - prostate-specific antigen - to test for prostate cancer. "We found that the effect of the guidelines recommending against the routine screening of elderly men in particular has been minimal at best," says Jesse Sammon, D.O., a researcher at Henry Ford's Vattikuti Urology Institute and lead author of the study.
The researchers found an estimated 17 million men age 50 or older without a history of prostate cancer or prostate problems who reported undergoing PSA screening. Though credited with a significant improvement in 5-year cancer survival rates during the first decade after the FDA approved PSA testing of men without symptoms, its use for routine screening is controversial.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|